DK0692970T3 - Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli - Google Patents

Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli

Info

Publication number
DK0692970T3
DK0692970T3 DK94914023T DK94914023T DK0692970T3 DK 0692970 T3 DK0692970 T3 DK 0692970T3 DK 94914023 T DK94914023 T DK 94914023T DK 94914023 T DK94914023 T DK 94914023T DK 0692970 T3 DK0692970 T3 DK 0692970T3
Authority
DK
Denmark
Prior art keywords
actin
contents
pathological
viscosity
sludge
Prior art date
Application number
DK94914023T
Other languages
English (en)
Inventor
Thomas P Stossel
Stuart E Lind
Paul A Janmey
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK0692970T3 publication Critical patent/DK0692970T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
DK94914023T 1993-04-02 1994-04-04 Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli DK0692970T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/042,247 US5464817A (en) 1990-04-11 1993-04-02 Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
PCT/US1994/003667 WO1994022465A1 (en) 1993-04-02 1994-04-04 Method for reducing the viscosity of pathological mucoid airway contents in the respiratoy tract

Publications (1)

Publication Number Publication Date
DK0692970T3 true DK0692970T3 (da) 1999-12-06

Family

ID=21920852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94914023T DK0692970T3 (da) 1993-04-02 1994-04-04 Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli

Country Status (17)

Country Link
US (2) US5464817A (da)
EP (1) EP0692970B1 (da)
JP (2) JPH08510998A (da)
KR (1) KR100308679B1 (da)
CN (1) CN1107521C (da)
AT (1) ATE182790T1 (da)
AU (1) AU695033B2 (da)
BR (1) BR9405856A (da)
CA (1) CA2159205A1 (da)
DE (1) DE69419907T2 (da)
DK (1) DK0692970T3 (da)
ES (1) ES2135576T3 (da)
GB (1) GB2293102B (da)
GR (1) GR3031753T3 (da)
NO (1) NO953862D0 (da)
SG (1) SG49574A1 (da)
WO (1) WO1994022465A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
CZ288633B6 (cs) * 1995-02-24 2001-08-15 Genentech, Inc. Na aktin rezistentní varianta lidské DNázy I a izolovaná nukleová kyselina ji kódující
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
MX9706429A (es) * 1995-02-24 1997-11-29 Genentech Inc Variantes de dnasa i humana.
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
WO1998024465A1 (en) 1996-12-04 1998-06-11 The Victoria University Of Manchester Wound healing and treatment of fibrosis
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
ES2321819T3 (es) * 2001-12-28 2009-06-12 Asubio Pharma Co., Ltd. Promotres del crecimiento y/o diferenciacion de celulas madre hematopoyeticas y/o progenitores hematopoyeticos.
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
WO2005004904A1 (fr) * 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes)
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
PL1694342T3 (pl) * 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
PL1755661T3 (pl) * 2004-05-12 2014-10-31 Brigham & Womens Hospital Inc Gelsolina do stosowania w leczeniu infekcji
EP1791566A4 (en) * 2004-08-06 2008-07-16 Nat Jewish Med & Res Center PRODUCT AND METHOD FOR PREVENTING THE DEVELOPMENT OF A BIOLOGICAL FILM
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
WO2007106577A2 (en) * 2006-03-15 2007-09-20 The Brigham And Women's Hospital, Inc. Gelsolin in the treatment and diagnosis of neurological disease
PT3279663T (pt) 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
PL2095825T3 (pl) * 2006-11-28 2011-12-30 Cls Therapeutics Ltd Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu
WO2008101084A2 (en) 2007-02-15 2008-08-21 National Jewish Medical And Research Center Methods and compositions for the disruption of biofilms
ES2634263T3 (es) * 2008-01-25 2017-09-27 The General Hospital Corporation Usos de diagnóstico terapéuticos de gelsolina en insuficiencia renal
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
EP3297657B1 (en) 2015-05-22 2020-03-25 GENKIN, Dmitry Dmitrievich Extracellular dna as a therapeutic target in neurodegeneration
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663050B2 (en) * 1990-04-11 1995-09-28 Brigham And Women's Hospital Therapeutic uses of actin-binding compounds
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis

Also Published As

Publication number Publication date
DE69419907T2 (de) 1999-12-09
AU6625094A (en) 1994-10-24
BR9405856A (pt) 1996-03-05
SG49574A1 (en) 1998-06-15
AU695033B2 (en) 1998-08-06
GR3031753T3 (en) 2000-02-29
KR100308679B1 (ko) 2001-11-30
CA2159205A1 (en) 1994-10-13
EP0692970B1 (en) 1999-08-04
CN1122108A (zh) 1996-05-08
GB9520020D0 (en) 1995-12-06
NO953862L (no) 1995-09-29
GB2293102A (en) 1996-03-20
DE69419907D1 (de) 1999-09-09
CN1107521C (zh) 2003-05-07
EP0692970A1 (en) 1996-01-24
WO1994022465A1 (en) 1994-10-13
JPH08510998A (ja) 1996-11-19
US5656589A (en) 1997-08-12
NO953862D0 (no) 1995-09-29
GB2293102B (en) 1996-10-09
US5464817A (en) 1995-11-07
ATE182790T1 (de) 1999-08-15
JP2001302537A (ja) 2001-10-31
ES2135576T3 (es) 1999-11-01

Similar Documents

Publication Publication Date Title
DK0692970T3 (da) Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli
DE69130289T2 (de) Therapeutische verwendung von actin-bindenden verbindungen
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
BRPI0214872B8 (pt) unidade peptídica e multipeptídica, método ex vivo para detectar auto-anticorpos de pacientes sofrendo de artrite reumatoide e para seleção de um peptídeo adequado para o diagnóstico da referida doença, e kit de diagnóstico
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
DE69635609D1 (de) Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung
ATE494304T1 (de) Immunspezifisch bindende antikörper gegen blys
BR9809951A (pt) Método para tratamento da obesidade
ATE233096T1 (de) Zusammensetzungen und methoden zur steigerung der darmfunktion
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
PT929669E (pt) Antigenios derivados das filagrinas e a sua utilizacao para o diagostico da poliartrite reumatoide
DE68907679D1 (de) Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweg-geschwuerkrankheiten.
ATE258797T1 (de) Verwendung von amifostin
DK0972032T3 (da) Peptider til behandling af systemisk lupus erythematosus
DE69824166D1 (de) Verwendung von vogel-antikörpern
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
BR9510323A (pt) Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica
BR0011178A (pt) Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma
BR9808866A (pt) Moléculas retinóicas relacionadas à inibição da superprodução de endotelina-1 em doenças
Satoh et al. Changing autoantibody profiles with variable clinical manifestations in a patient with relapsing systemic lupus erythematosus and polymyositis
TR199900555T2 (xx) Vir�slerin v�cuda yeniden yerle�mesini �nleyici madde olarak proteinerin kullan�m�.
Thachil et al. What is your diagnosis?: An elderly lady with rheumatoid arthritis and recurrent monoarthritis
Johnson Tango
DE3586795T2 (de) Absorptionsverbesserer fuer proteine.
RU96123360A (ru) Способ лечения сепсиса у новорожденных